Tvardi Therapeutics, Inc. Common Stock
TVRD XNASAbout Tvardi Therapeutics, Inc. Common Stock
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $0 | $-6,457,000 | $-0.69 |
| Q1 2026 | $0 | $-6,804,000 | $-0.73 |
| FY 2025 | $0 | $-18,214,000 | $-2.46 |
| Q3 2025 | $0 | $-5,527,000 | $-0.59 |
Earnings & Analyst Ratings
TickerDaily Coverage
Get TVRD Alerts
Stay ahead with breaking news, price alerts, and expert analysis on Tvardi Therapeutics, Inc. Common Stock.